Patents by Inventor Rainer Mussmann

Rainer Mussmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS
    Publication number: 20220195061
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating T1DM, by employing anti-CD40 antibodies.
    Type: Application
    Filed: May 6, 2020
    Publication date: June 23, 2022
    Inventors: Pascal ESPIE, Allison GOLDFINE, Rainer MUSSMANN, James RUSH
  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20160060317
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: April 8, 2015
    Publication date: March 3, 2016
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Neurturin conjugates for pharmaceutical use
    Patent number: 9029323
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: May 12, 2015
    Assignee: Evotec International GmbH
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20130231283
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: February 1, 2013
    Publication date: September 5, 2013
    Applicant: DeveloGen Aktiengesellschaft
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Use of azapaullones for preventing and treating pancreatic autoimmune disorders
    Patent number: 7968535
    Abstract: This invention relates to the use of azapaullones, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA and neurodegenerative disorders.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: June 28, 2011
    Assignees: Develogen Atkiengesellschaft, Technische Universitaet Carolo-Wilhelmina Zu Braunschweig
    Inventors: Rainer Mussmann, Conrad Peter Kunick, Hendrik Stukenbrock, Marcus Geese, Simone Kegel, Ulrike Burk
  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20110003741
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: May 5, 2010
    Publication date: January 6, 2011
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders
    Publication number: 20080287423
    Abstract: This invention relates to the use of azapaullones, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA and neurodegenerative disorders.
    Type: Application
    Filed: May 4, 2006
    Publication date: November 20, 2008
    Inventors: Rainer Mussmann, Conrad Peter Kunick, Hendrik Stukenbrock, Marcus Geese, Simone Kegel, Ulrike Burk
  • Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
    Publication number: 20080207594
    Abstract: This invention relates to the use of Pax4 stimulating compounds, e.g. Glycogen synthase kinase-3 (GSK-3) inhibitors, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA. More particularly, this invention relates to the use of compounds selected from paullones, indirubines, substituted ureas, maleimide derivatives and pyrimidine thiones. Further, the present invention relates to a method of identifying and/or characterizing pancreatic beta-cell mitogens by using cells expressing a pancreatic gene or a gene whose function is controlled by a pancreatic gene, particularly the Pax4 gene, and which are transfected with a reporter gene.
    Type: Application
    Filed: May 4, 2006
    Publication date: August 28, 2008
    Applicant: Davelogen Aktiengesellschaft
    Inventors: Rainer Mussmann, Matthias Austen, Arndt-Rene Kelter, Friedrich Harder, Babette Aicher, Alexander Lomow